Tscan Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
830 Winter St, Waltham, Massachusetts, 0...Phone Number
(857) 399-9500Website
www.tscan.comRevenue
$9.1 MillionStock Symbol
TCRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Tscan Therapeutics
TScan Therapeutics is a clinical-stage biopharmaceutical company, Dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. Founded in early 2018 and headquartered in Waltham, MA.Explore more
Tscan Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tscan Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Tscan Therapeutics is spiking on competitors!
Check if Tscan Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Tscan Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Tscan Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Tscan Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Tscan Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Tscan Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Tscan Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Tscan Therapeutics
Compare insights from companies similar to Tscan Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tscan Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tscan Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tscan Therapeutics.
Tscan Therapeutics financials insights
Gather financial insights about Tscan Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$2.5M
2020
Series B
$83M
2021
Series C
$100M
Share Placement
$100M
2022
Debt
$60M
2024
Debt
$52.5M
Tscan Therapeutics Tech Stack
A closer look at the technologies used by Tscan Therapeutics
Most Recent Scoops
Open Position
Open Position
Person-Based
Manufacturing Operations
Hiring Plans
Tscan Therapeutics is hiring in Operations for the first time in 12 months. Areas of expertise include: Process Improvement, Inventory Management, Manufacturing Operations, Production Process, Equipment Maintenance, Supply Chain, and Current Good Manufacturing Practices (cGMPS).
Hiring Plans
Open Position
Tscan Therapeutics News & Media
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29ᵗʰ Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually.TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tscan Therapeutics
Sign Up For FreeTo access detailed company insights
TScan Therapeutics is a clinical-stage biopharmaceutical company, Dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. Founded in early 2018 and headquartered in Waltham, MA.... Read More
